English  |  正體中文  |  简体中文  |  總筆數 :2856713  
造訪人次 :  53609287    線上人數 :  1031
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"sequist l v"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 16-25 / 40 (共4頁)
<< < 1 2 3 4 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2020-05-26T09:26:58Z Reply to F. de Marinis et al Chih-Hsin Yang;Sequist L.V.; CHIH-HSIN YANG; Sequist L.V.
臺大學術典藏 2020-05-26T09:26:57Z Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 CHIH-HSIN YANG; Sequist L.V; Geater S.L; Tsai C.-M; Mok T.S.K; Schuler M; Yamamoto N; Yu C.-J; Ou S.H.I; Zhou C; Massey D; Zazulina V; Wu Y.-L.; Wu Y.-L.;Zazulina V;Massey D;Zhou C;Ou S.H.I;Yu C.-J;Yamamoto N;Schuler M;Mok T.S.K;Tsai C.-M;Geater S.L;Sequist L.V;Chih-Hsin Yang
臺大學術典藏 2020-05-26T09:26:54Z Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials Sequist L.V.;Zazulina V;Shahidi M;Massey D;Kato T;Lee K.H;Su W.-C;Boyer M;Mok T;Orlov S;Bennouna J;Hirsh V;Gorbunova V;Tsai C.-M;Lee K.Y;Geater S.L;Huang Y;Lu S;Feng J;O'Byrne K;Hu C.-P;Zhou C;Yamamoto N;Popat S;Sebastian M;Schuler M;Wu Y.-L;Chih-Hsin Yang; CHIH-HSIN YANG; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V.
臺大學術典藏 2020-05-26T09:26:51Z Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials Shah R; Märten A; Massey D; Wind S; Wu Y.-L.; Dickgreber N; Okamoto I; Sebastian M; Huang Y; Hirsh V; Lu S; O'Byrne K; Feng J; Wu Y.-L.;Wind S;Massey D;M?rten A;Shah R;Dickgreber N;Okamoto I;Sebastian M;Huang Y;Hirsh V;Lu S;O'Byrne K;Feng J;Yamamoto N;Hu C.-P;Mok T;Geater S.L;Schuler M;Zhou C;Sequist L.V;Chih-Hsin Yang; CHIH-HSIN YANG; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N
臺大學術典藏 2020-05-26T09:26:48Z First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases Chih-Hsin Yang;Zazulina V;Massey D;Sequist L.V;Popat S;Mok T;Yamamoto N;O'Byrne K;Hirsh V;Wu Y.-L;Schuler M; Schuler M; Wu Y.-L; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist L.V; Massey D; Zazulina V; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:46Z 138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) Wu Y.-L.;Shah R;Mok T;Hirsh V;O'Byrne K;Zhou C;Yamamoto N;Sequist L.V;Chih-Hsin Yang;Schuler M; Schuler M; CHIH-HSIN YANG; Sequist L.V; Yamamoto N; Zhou C; O'Byrne K; Hirsh V; Mok T; Shah R; Wu Y.-L.
臺大學術典藏 2020-05-26T09:26:44Z Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Keynote-021 Investigators;Gandhi L;Raftopoulos H;Ge Y;Fiore J;Awad M.M;Sequist L.V;Gubens M;Chih-Hsin Yang;Panwalkar A;Jalal S.I;Stevenson J.P;Martins R.G;Gentzler R.D;Powell S.F;Patnaik A;Papadimitrakopoulou V.A;Borghaei H;Gadgeel S.M;Langer C.J; Langer C.J; Gadgeel S.M; Borghaei H; Papadimitrakopoulou V.A; Patnaik A; Powell S.F; Gentzler R.D; Martins R.G; Stevenson J.P; Jalal S.I; Panwalkar A; CHIH-HSIN YANG; Gubens M; Sequist L.V; Awad M.M; Fiore J; Ge Y; Raftopoulos H; Gandhi L; KEYNOTE-021 investigators
臺大學術典藏 2020-05-26T09:26:40Z EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: Analysis of LUX-Lung 3 and 6 Chih-Hsin Yang;Kim M;Massey D;Gibson N;Hirsh V;O'Byrne K;Yamamoto N;Mok T;Schuler M;Hou M;Li W;Huang Y;Lu S;Feng J;Hu C.-P;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Hu C.-P; Feng J; Lu S; Huang Y; Li W; Hou M; Schuler M; Mok T; Yamamoto N; O'Byrne K; Hirsh V; Gibson N; Massey D; Kim M; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:38Z Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Lin C.-C;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin C.-C; Mann H; Cantarini M; Ghiorghiu S; Jänne P.A.
臺大學術典藏 2020-05-26T09:26:37Z Scientific Advances in Thoracic Oncology 2016 Spigel D.R.;Hirsch F.R;Gandara D.R;Scagliotti G.V;Leighl N.B;Kelly R.J;Baas P;Tsao A;Rudin C.M;Faivre-Finn C;Wynes M.W;Peters S;Gettinger S;Horn L;Patel J.D;Costa D.B;Ahn M.-J;Shaw A.T;Sequist L.V;Chih-Hsin Yang;Johnson M;Kim D.-W;Solomon B;Senan S;Higgins K;Wu Y.-L;Wakelee H.A;Donington J;Asamura H;Lim E;Detterbeck F.C;Rami-Porta R;Dacic S;Bubendorf L;Yatabe Y;Mulshine J.L;Groen H.J.M;Field J.K;Jett J.R;Cummings K.M;Stone E.C.A;Soo R.A; Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R.

顯示項目 16-25 / 40 (共4頁)
<< < 1 2 3 4 > >>
每頁顯示[10|25|50]項目